ArticleImmunity, inflammation and disease2026
Exosomal miR-1246 in Syphilis Serofast State: Diagnostic Value and NLRP3 Inflammasome Suppression.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exosomal miR-1246 in Syphilis Serofast State: Diagnostic Value and NLRP3 Inflammasome Suppression.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSerofast state (SF), defined as persistent low-titer antibodies after treatment, poses a diagnostic challenge because of the overlap with serologic features of active infection. Exosomal miRNAs are stable in body fluids and have potential as diagnostic markers.
objectivesThis study aimed to identify plasma exosomal miR-1246 as a diagnostic biomarker for SF and elucidate its role in NLRP3 inflammasome suppression, providing mechanistic insights into SF pathogenesis.
methodsUsing microarray analysis and reverse transcription quantitative polymerase chain reaction (RT-qPCR), differential miRNA expression was measured in the plasma samples of SF patients. Microarray analysis, target gene prediction, and Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were conducted to identify differentially expressed microRNAs (DEmiRNAs). The plasma levels of NLRP3 and related cytokines were quantified using enzyme-linked immunosorbent assay (ELISA), and the regulatory effect of miR-1246 on NLRP3 was measured in vitro. Diagnostic performance was assessed based on receiver operating characteristic (ROC) curve analysis for miR-1246 alone and in combination with the rapid plasma reagin (RPR) test.
resultsPlasma exosomal miR-1246 was significantly upregulated in SF patients (p < 0.001), whereas NLRP3 and its associated factors were downregulated (p < 0.05). In vitro experiments confirmed that miR-1246 negatively regulated NLRP3 inflammasome activity. GO and KEGG analyses revealed that the target genes of DEmiRNAs were involved in multiple biological processes and signalling pathways. ROC analysis showed that miR-1246 alone yielded an area under the curve (AUC) of 0.760 (sensitivity 77.4%, specificity 62.9%). When combined with RPR, the AUC increased to 0.824 (sensitivity 83.3%, specificity 65.7%).
conclusionsExosomal miR-1246 is elevated in SF and may contribute to its pathogenesis by inhibiting NLRP3 inflammasome. It demonstrates potential as a diagnostic biomarker, particularly when combined with RPR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.